Helsinn and Chugai Renew Partnership to Market AKYNZEO® in UK and Ireland

Helsinn Group and Chugai Pharma Europe have renewed their partnership agreement to distribute and license AKYNZEO® in the UK and Ireland. AKYNZEO® is a treatment for chemotherapy-induced nausea and vomiting in adults. This announcement was made on June 12, 2024.

Helsinn Group, a global pharmaceutical company with a focus on supportive care, oncology, and dermato-oncology, has been in operation for over 45 years. Chugai Pharma Europe, the European subsidiary of Japan's Chugai Pharmaceutical Co., Ltd., is a leading research-based pharmaceutical company.

Troy Robinson, Managing Director at Chugai Pharma Europe, expressed delight in continuing the collaboration with Helsinn. He stated that oncology remains a crucial aspect of Chugai's business, and this agreement underscores their commitment to enhancing cancer care. Robinson emphasized that their joint efforts would ensure continued support for patients in the UK and Ireland, providing access to AKYNZEO® as a valuable supportive care product.

Dr. Melanie Rolli, CEO of Helsinn Group, highlighted the renewed agreement as a significant milestone, noting that Chugai has been an exceptional partner over the past decade. Rolli stressed the shared vision and values between the two companies, which focus on supportive care and improving the quality of life for cancer patients. She looked forward to new opportunities, building on the strong foundation already established with Chugai.

AKYNZEO® is notable for being the first and only fixed combination of 5-HT3 and NK1 receptor antagonists approved in adults for preventing both acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy.

Chugai Pharma Europe, headquartered in London, coordinates Chugai’s commercial, medical, and business activities in Europe, primarily focusing on oncology, rheumatology, and hematology. Chugai Pharma Europe also supports clinical research programs for Japan and explores co-development and in-licensing opportunities with an established network of partners.

Helsinn, headquartered in Lugano, Switzerland, builds, manufactures, launches, and commercializes products aimed at improving the quality of life for patients with cancer and chronic diseases. With operations in the U.S. and partnerships in over 90 countries, Helsinn combines extensive pharmaceutical and technical expertise, emphasizing integrity, passion, and quality. Established in 1976, Helsinn is a third-generation family-owned company committed to innovation and sustainable growth.